Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2009 Aug;8(8):611-2. doi: 10.1038/nrd2946.

Tolvaptan.

Author information

  • 1Harper University Hospital, 3990 John R Street, 9 Webber Core, Detroit, MI 48201, USA. JGhali@dmc.org

Abstract

In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.

PMID:
19644472
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk